News >

Ramucirumab Improves Survival in Second-Line HCC

Jason Harris
Published: Wednesday, Apr 04, 2018

Levi Garraway, MD, PhD

Levi Garraway, MD, PhD
Ramucirumab (Cyramza) extended overall survival (OS) versus placebo as a second-line treatment for patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein (AFP), according to findings from the phase III REACH-2 trial.

Ramucirumab currently has approved FDA indications for lung cancer, colorectal cancer, and gastric or gastroesophageal junction adenocarcinoma.

References

  1. Zhu AX, Ryoo B-Y, Yen C-J, et al. Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): analysis of patients with elevated α-fetoprotein (AFP) from the randomized phase III REACH study. Presented at: 2015 Gastrointestinal Cancers Symposium; January 15-17, 2015; San Francisco, CA. Abstract 232.
  2. Zhu AX, Park JO, Ryoo B-Y, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015; 16(7):859-70. doi: 10.1016/S1470-2045(15)00050-9.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x